Ixazomib versus Lenalidomide or Ixazomib and Lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China

被引：0

作者：

Zhuang, Zhe ^{[1
]}

Yu, Hong ^{[2
]}

Liu, Qinhua ^{[3
]}

Zou, Dongmei ^{[4
]}

Shi, Lei ^{[5
]}

Tian, Ying ^{[6
]}

Dong, Fei ^{[7
]}

Ma, Yanping ^{[8
]}

Tian, Wei-wei ^{[9
]}

Feng, Ru ^{[10
]}

Liu, Shuangjiao

Liu, Hui ^{[10
]}

Ma, Liang-Ming

Jing, Hongmei

Chen, Wenming

Wu, Yin

Bao, Li

Sun, Wanling ^{[4
]}

Fu, Rong ^{[2
]}

Zhuang, Junling ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China

[2] Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin, Peoples R China

[3] Anhui Med Univ, Dept Hematol, Affiliated Hosp 1, Hefei, Peoples R China

[4] Capital Med Univ, Dept Hematol, Xuanwu Hosp, Beijing, Peoples R China

[5] Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China

[6] Capital Med Univ, Dept Hematol, Beijing Chao Yang Hosp, Beijing, Peoples R China

[7] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China

[8] Shanxi Med Univ, Dept Hematol, Hosp 2, Taiyuan, Peoples R China

[9] Shanxi Med Univ, Dept Hematol, Shanxi Bethune Hosp, Taiyuan, Peoples R China

[10] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Natl Ctr Gerontol, Beijing, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-142

引用

页码：S113 / S113

页数：1

共 50 条

[1] Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China
Zhuang, Zhe
Tian, Ying
Yu, Hong
Shi, Lei
Tian, Wei-wei
Liu, Qinhua
Zou, Dongmei
Dong, Fei
Ma, Yanping
Feng, Ru
Liu, Shuangjiao
Liu, Hui
Jing, Hongmei
Sun, Wanling
Ma, Liang-Ming
Bao, Li
Wu, Yin
Chen, Wenming
Zhuang, Junling
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S54 - S55
[2] Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China
Zhe Zhuang
Ying Tian
Hong Yu
Lei Shi
Tian, Wei-wei
Liu, Qinhua
Zou, Dongmei
Fei Dong
Ma, Yanping
Ru Feng
Liu, Shuangjiao
Hui Liu
Jing, Hongmei
Sun, Wanling
Ma, Liangming
Li Bao
Rong Fu
Yin Wu
Chen Wenming
Zhuang, Junling
[J]. BLOOD, 2022, 140 : 12637 - 12639
[3] Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China
Zhuang, Zhe
Tian, Ying
Tian, Wei-wei
Yu, Hong
Zou, Dongmei
Liu, Qinhua
Shi, Lei
Dong, Fei
Ma, Yanping
Feng, Ru
Liu, Shuangjiao
Liu, Hui
Jing, Hongmei
Bao, Li
Sun, Wanling
Fu, Rong
Ma, Liangming
Chen Wenming
Wu, Yin
Zhuang, Junling
[J]. BLOOD, 2021, 138
[4] Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for transplant-ineligible multiple myeloma: update of a multi-center prospective study in China
Zhuang, Zhe
Tian, Ying
Yu, Hong
Shi, Lei
Tian, Wei-wei
Liu, Qinhua
Zou, Dongmei
Dong, Fei
Feng, Ru
Ma, Yanping
Liu, Shuangjiao
Liu, Hui
Jing, Hongmei
Sun, Wanling
Ma, Liang-Ming
Bao, Li
Fu, Rong
Wu, Yin
Chen, Wenming
Zhuang, Junling
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S104 - S104
[5] Ixazomib and lenalidomide maintenance therapy in multiple myeloma
Ricardo D. Parrondo
Victoria Alegria
Vivek Roy
Taimur Sher
Asher A. Chanan-Khan
Sikander Ailawadhi
[J]. Annals of Hematology, 2021, 100 : 851 - 853
[6] Ixazomib and lenalidomide maintenance therapy in multiple myeloma
Parrondo, Ricardo D.
Alegria, Victoria
Roy, Vivek
Sher, Taimur
Chanan-Khan, Asher A.
Ailawadhi, Sikander
[J]. ANNALS OF HEMATOLOGY, 2021, 100 (03) : 851 - 853
[7] Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
Michael Slade
Thomas G. Martin
Nitya Nathwani
Mark A. Fiala
Michael P. Rettig
Feng Gao
Abhinav Deol
Francis K. Buadi
Jonathan L. Kaufman
Craig C. Hofmeister
Tara K. Gregory
Jesus Berdeja
Ajai Chari
Ashley Rosko
Ravi Vij
[J]. Leukemia, 2022, 36 : 2917 - 2921
[8] Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
Slade, Michael
Martin, Thomas G.
Nathwani, Nitya
Fiala, Mark A.
Rettig, Michael P.
Gao, Feng
Deol, Abhinav
Buadi, Francis K.
Kaufman, Jonathan L.
Hofmeister, Craig C.
Gregory, Tara K.
Berdeja, Jesus
Chari, Ajai
Rosko, Ashley
Vij, Ravi
[J]. LEUKEMIA, 2022, 36 (12) : 2917 - 2921
[9] Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
Patel, Krina K.
Shah, Jatin J.
Feng, Lei
Lee, Hans C.
Manasanch, Elisabet M.
Olsem, Jasper
Morphey, Ashley
Huo, Xiao Jiao
Thomas, Sheeba K.
Bashir, Qaiser
Qazilbash, Muzaffar H.
Weber, Donna M.
Orlowski, Robert Z.
[J]. CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1277 - 1284
[10] Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial
Vij, Ravi
Martin, Thomas G., III
Nathwani, Nitya
Fiala, Mark A.
Gao, Feng
Deol, Abhinav
Buadi, Francis K.
Kaufman, Jonathan L.
Hofmeister, Craig C.
Gregory, Tara K.
Berdeja, Jesus G.
Chari, Ajai
Rosko, Ashley E.
[J]. BLOOD, 2019, 134

← 1 2 3 4 5 →